Evidence map›Paper›PMID 19720633›Full record

ArticleEuropean heart journal2009

Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.

Mark J Alberts, Deepak L Bhatt, Jean-Louis Mas, E Magnus Ohman, Alan T Hirsch, Joachim Röther, Geneviève Salette, Shinya Goto, Sidney C Smith, Chiau-Suong Liau and 3 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 6 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 6 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Trial
  8. Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2021
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 6 countries.

Mark J AlbertsDepartment of Neurology, Northwestern University Medical School, 710 N Lake Shore Drive, Room 1420, Chicago, IL 60611, USA. m-alberts@northwestern.edu
Deepak L Bhatt
Jean-Louis Mas
E Magnus Ohman
Alan T Hirsch
Joachim Röther
Geneviève Salette
Shinya Goto
Sidney C Smith
Chiau-Suong Liau
Peter W F Wilson
Ph Gabriel Steg
REduction of Atherothrombosis for Continued Health Registry Investigators
Université Paris Cité · FRDuke University · USEmory University · USHarvard University Press · USMedizinische Hochschule Hannover · DENational Taiwan University · TWNorthwestern University · USSanofi (Mexico) · MXTokai University · JPTwin Cities Orthopedics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo determine 3-year event rates in outpatients with vascular disease enrolled in the REduction of Atherothrombosis for Continued Health (REACH) Registry. METHODS AND

resultsREACH enrolled 67 888 outpatients with atherothrombosis [established coronary artery disease (CAD), cerebrovascular disease, or peripheral arterial disease (PAD)], or with at least three atherothrombotic risk factors, from 44 countries. Among the 55 499 patients at baseline with symptomatic disease, 39 675 were eligible for 3-year follow-up, and 32 247 had data available (81% retention rate). Among the symptomatic patients at 3 years, 92% were taking an antithrombotic agent, 91% an antihypertensive, and 76% were on lipid-lowering therapy. For myocardial infarction (MI)/stroke/vascular death, 1- and 3-year event rates for all patients were 4.2 and 11.0%, respectively. Event rates (MI/stroke/vascular death) were significantly higher for patients with symptomatic disease vs. those with risk factors only at 1 year (4.7 vs. 2.3%, P < 0.001) and at 3 years (12.0 vs. 6.0%, P < 0.001). One and 3-year rates of MI/stroke/vascular death/rehospitalization were 14.4 and 28.4%, respectively, for patients with symptomatic disease. Rehospitalization for a vascular event other than MI/stroke/vascular death was common at 3 years (19.0% overall; 33.6% for PAD; 23.0% for CAD). For patients with symptomatic vascular disease in one vascular bed vs. multiple vascular beds, 3-year event rates for MI/stroke/vascular death/rehospitalization were 25.5 vs. 40.5% (P < 0.001).

conclusionDespite contemporary therapy, outpatients with symptomatic atherothrombotic vascular disease experience high rates of recurrent vascular events and rehospitalizations.

Indexed as

AgedAmbulatory CareAnticoagulantsAntihypertensive AgentsCoronary Artery DiseaseDiabetes ComplicationsFemaleFollow-Up StudiesHospitalizationHumansHypertensionHypoglycemic AgentsMaleMyocardial InfarctionObesityPeripheral Vascular DiseasesAnticoagulantsAntihypertensive AgentsHypoglycemic Agents

Identifiers

PMID19720633
PMCPMC2755116
OpenAlexW2135989027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.